$ 16.36
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of MESO is 27 and suggests 68% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
